Jaktinib

Generic Name
Jaktinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Jaktinib
Drug: Placebo
First Posted Date
2024-01-05
Last Posted Date
2024-12-12
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
32
Registration Number
NCT06193148
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhu, Jiangsu, China

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Phase 3
Recruiting
Conditions
Ankylosing Spondylitis
Interventions
Drug: Jaktinib
First Posted Date
2023-05-16
Last Posted Date
2024-01-11
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
258
Registration Number
NCT05861128
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Phase 3
Recruiting
Conditions
Ankylosing Spondylitis
Interventions
Drug: Jaktinib
Drug: Placebo
First Posted Date
2023-05-16
Last Posted Date
2024-12-12
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
258
Registration Number
NCT05861102
Locations
🇨🇳

RenJi Hospital, Shanghai, Shanghai, China

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Phase 2
Not yet recruiting
Conditions
COVID-19 Pneumonia
Interventions
Drug: Jaktinib
Drug: Placebo
First Posted Date
2023-01-05
Last Posted Date
2023-01-17
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
60
Registration Number
NCT05672888
Locations
🇨🇳

The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou, Zhejiang, China

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Phase 3
Active, not recruiting
Conditions
Alopecia Areata
Interventions
Drug: Jaktinib
First Posted Date
2022-02-24
Last Posted Date
2024-12-12
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
315
Registration Number
NCT05255237
Locations
🇨🇳

11 Xizhimen South Street, Beijing, Beijing, China

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Phase 3
Active, not recruiting
Conditions
Alopecia Areata
Interventions
Drug: placebo
Drug: Jaktinib
First Posted Date
2021-09-21
Last Posted Date
2024-12-12
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
425
Registration Number
NCT05051761
Locations
🇨🇳

Hospital for Skin Diseases, Chinese Academy of medical Sciences, Nanjing, Jiangsu, China

🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

First Posted Date
2021-04-29
Last Posted Date
2022-12-01
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
1
Registration Number
NCT04866056
Locations
🇨🇳

79 Qingchun Road, Hangzhou, Zhejiang, China

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

First Posted Date
2020-11-05
Last Posted Date
2023-11-13
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
105
Registration Number
NCT04617028
Locations
🇨🇳

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

Phase 2
Active, not recruiting
Conditions
Moderate-to-Severe Plaque Psoriasis
Interventions
Drug: Jaktinib
Drug: Placebo
First Posted Date
2020-11-03
Last Posted Date
2024-03-06
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
123
Registration Number
NCT04612699
Locations
🇨🇳

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: placebo
Drug: Jaktinib
First Posted Date
2020-09-07
Last Posted Date
2023-03-24
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
166
Registration Number
NCT04539639
Locations
🇨🇳

The second xiangya hospital of central south university, Changsha, Hunan, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy